Enhancement of hematopoietic stem cell engraftment by inhibition of CXCL12 proteolysis with sitagliptin, an oral dipeptidyl-peptidase IV inhibitor: a report in a case of delayed graft failure.
Daniele
D
Focosi
Richard Eric
RE
Kast
Maria Rita
MR
Metelli
Edoardo
E
Benedetti
Sara
S
Galimberti
Federico
F
Papineschi
Mario
M
Petrini
D002455:Cell Division; D054377:Chemokine CXCL12 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D054873:Dipeptidyl-Peptidase IV Inhibitors; D005260:Female; D006084:Graft Rejection; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000187:drug effects*; D006801:Humans; D006868:Hydrolysis; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000601:surgery*; D008875:Middle Aged; D011480:Protease Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D011719:Pyrazines / Q000494:pharmacology* / Q000627:therapeutic use; D000068900:Sitagliptin Phosphate; D014230:Triazoles / Q000494:pharmacology* / Q000627:therapeutic use
D054377:Chemokine CXCL12; D054873:Dipeptidyl-Peptidase IV Inhibitors; D011480:Protease Inhibitors; D011719:Pyrazines; D014230:Triazoles; D000068900:Sitagliptin Phosphate